An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- change in 24-hour sodium excretion compared to baseline
研究概览
简要总结
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.
详细描述
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.
排除标准
- •Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.
研究组 & 干预措施
CHF Patients: ER Torsemide 40 mg
CHF patients will be given 40 mg ER Torsemide
干预措施: CHF Patients: ER Torsemide 40 mg (Drug)
CHF Patients: Furosemide 40 mg
CHF patients are on 40 mg of Furosemide
干预措施: CHF Patients: Furosemide 40 mg (Drug)
结局指标
主要结局
change in 24-hour sodium excretion compared to baseline
时间窗: 24 hours
the difference in 24 hour sodium excretion between ER Torsemide and Furosemide
次要结局
- Changes in body weight(2 weeks)